Salloum-Asfar Salam, Ltaief Samia M, Taha Rowaida Z, Nour-Eldine Wared, Abdulla Sara A, Al-Shammari Abeer R
Neurological Disorders Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar.
College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar.
Int J Mol Sci. 2025 Feb 26;26(5):2044. doi: 10.3390/ijms26052044.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder in which early diagnosis is critical for effective intervention and improved outcomes. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and have emerged as promising biomarkers for neurological disorders, including ASD. In our previous discovery study, we identified dysregulated expression of several miRNAs in the plasma samples of children with ASD aged 5-12 years. In this study, we aimed to validate these findings in a younger cohort with ASD (aged 2-4 years) and assess their potential use as biomarkers for the early diagnosis of ASD. A total of 108 young children aged 2-4 years were recruited, including 66 children with ASD and 42 age- and sex-matched controls. Using next-generation sequencing and advanced bioinformatics, we validated the differential expression of 17 miRNAs in ASD, which showed consistent dysregulation across both the current and previous cohorts. We also observed significant correlations between several miRNAs and participants' age, suggesting that age is a key factor influencing dynamic miRNA changes, particularly in the ASD group. Pathway analysis linked these miRNAs to critical regulatory networks involved in neurodevelopment and immune responses. Finally, we found that a combination of four miRNAs (miR-4433b-5p, miR-15a-5p, miR-335-5p, and miR-1180-3p) exhibited high diagnostic accuracy, with an area under the curve (ROC-AUC) of 0.936 (95% CI = 0.892, 0.980; < 0.001). These findings support the use of this four-miRNA panel as a robust biomarker for early ASD diagnosis and lay the groundwork for future research into miRNA-based diagnostic tools and therapeutic strategies for ASD.
自闭症谱系障碍(ASD)是一种神经发育障碍,早期诊断对于有效干预和改善预后至关重要。微小RNA(miRNA)是一类调节基因表达的小非编码RNA,已成为包括ASD在内的神经系统疾病有前景的生物标志物。在我们之前的发现性研究中,我们在5至12岁ASD儿童的血浆样本中鉴定出几种miRNA的表达失调。在本研究中,我们旨在在年龄更小的ASD队列(2至4岁)中验证这些发现,并评估它们作为ASD早期诊断生物标志物的潜在用途。总共招募了108名2至4岁的幼儿,包括66名ASD儿童和42名年龄及性别匹配的对照。使用下一代测序和先进的生物信息学,我们验证了17种miRNA在ASD中的差异表达,其在当前和先前队列中均表现出一致的失调。我们还观察到几种miRNA与参与者年龄之间存在显著相关性,表明年龄是影响miRNA动态变化的关键因素,尤其是在ASD组中。通路分析将这些miRNA与参与神经发育和免疫反应的关键调控网络联系起来。最后,我们发现四种miRNA(miR-4433b-5p、miR-15a-5p、miR-335-5p和miR-1180-3p)的组合具有较高的诊断准确性,曲线下面积(ROC-AUC)为0.936(95%CI = 0.892, 0.980;P < 0.001)。这些发现支持将这种四种miRNA组合用作ASD早期诊断的可靠生物标志物,并为未来基于miRNA的诊断工具和ASD治疗策略的研究奠定了基础。